Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review-Reference-Cited by-同舟云学术

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review

Published:2019-12-01 Issue:4 Volume:6 Page:MMT33
ISSN:2045-0885
Container-title:Melanoma Management
language:en
Short-container-title:Melanoma Management

Author:

Mohr Peter¹,Kiecker Felix²,Soriano Virtudes³,Dereure Olivier⁴,Mujika Karmele⁵,Saiag Philippe⁶,Utikal Jochen⁷,Koneru Rama⁸,Robert Caroline⁹,Cuadros Florencia¹⁰,Chacón Matias¹¹,Villarroel Rodrigo U¹²,Najjar Yana G¹³,Kottschade Lisa¹⁴,Couselo Eva M¹⁵,Koruth Roy¹⁶,Guérin Annie¹⁷,Burne Rebecca¹⁷,Ionescu-Ittu Raluca¹⁷,Perrinjaquet Maurice¹⁸,Zager Jonathan S¹⁹

Affiliation:

1. Department of Dermatology, Elbe Kliniken, Stade, Germany

2. Department of Dermatology and Allergy, Skin Cancer Center, Charité Universitätsmedizin Berlin, Berlin, Germany

3. Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain

4. Department of Dermatology and INSERM U1058 ‘pathogenesis and control of chronic infections’, University of Montpellier, Montpellier, France

5. Department of Medical Oncology, Onkologikoa-Oncology Institute Gipuzkoa, Gipuzkoa, Spain

6. Department of General and Oncologic Dermatology Ambroise Paré Hospital, APHP; EA 4340 ‘Biomarkers in cancerology and hemato-oncology’, UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France

7. Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany and Department of Dermatology, Venereology and Allergology; University Medical Center, Ruprecht-Karl University of Heidelberg, Mannheim, Germany

8. RS McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, Oshawa, Ontario, Canada

9. Dermatology Unit, Gustave Roussy and Paris-Saclay University, Villejuif, France

10. Medical Oncology, Instituto de Oncologia de Rosario, Rosario, Santa Fe, Argentina

11. Departments of Medical and Surgical Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina

12. Cancer Institute São Vicente de Paulo, Passo Fundo, RS, Brazil

13. UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA

14. Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA

15. Department of Medical Oncology, Vall d'Hebron Hospital and VHIO (Vall d'Hebron Institute of Oncology), Barcelona, Spain

16. Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA

17. Analysis Group, Inc. Montreal, Quebec, Canada

18. Navigant Germany GmbH, Berlin, Germany

19. Departments of Cutaneous Oncology and Sarcoma, Moffitt Cancer Center, Tampa, FL 33612, USA

Abstract

Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011–2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe. Results: Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy. Conclusion: Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma.

Publisher

Future Medicine Ltd

Subject

Dermatology,Oncology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/mmt-2019-0015

Reference55 articles.

1. American Cancer Society. Key statistics for melanoms skin cancer (2019). https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html

2. Epidemiology of Melanoma

3. World Health Organization: International Agency for Research on Cancer. World – incidence, mortality and prevalence by cancer site (2019). http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf

4. Continued Increase in Melanoma Incidence across all Socioeconomic Status Groups in California, 1998–2012

5. A novel phenotype with features of basal cell nevus syndrome and basaloid follicular hamartoma syndrome

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma;Melanoma Research;2024-05-27

2. Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US;BMC Cancer;2024-03-27

3. Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics;Future Oncology;2022-10

4. [Translated article] Epidemiology of Melanoma in Spain: Estimation of Number of Patients With Stage III Disease Eligible for Adjuvant Therapies;Actas Dermo-Sifiliográficas;2022-04

5. Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique;Future Oncology;2021-06